Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clarus Therapeutics Holdings
Northbrook, Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Clarus Therapeutics developed and commercialized JATENZO (testosterone undecanoate), which received FDA approval in March 2019 as the first and only FDA-approved oral softgel testosterone replacement therapy (TRT) for adult males with testosterone deficiency. JATENZO launched in February 2020. The company went out of business with its liquidation plan becoming effective on February 28, 2023. Subsequently, Tolmar acquired JATENZO.
- Therapeutic areas
- OncologyEndocrinologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
HavaH Therapeutics (licensing agreement for androgen therapies for inflammatory breast disease and breast cancer)McGill University/The Royal Institution for the Advancement of Learning (licensing agreement for CoQ10 deficiency treatment technology)St. Louis UniversityUniversity of Miami (clinical trial sponsors)
Beyond the preview
Go deeper on Clarus Therapeutics Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clarus Therapeutics Holdings.